5-Alpha-reductase inhibitor and benign prostatic hypertrophy; Impact on size

Benign prostatic hyperplasia is a relatively frequent condition in senior men, particularly those over 50, and is generally defined as a thickening of the prostate gland. Lower urinary tract discomfort might impact 30% of males over the age of 65 in total. This study aimedto evaluate the impact of 5 alpha-reductase inhibitors, alpha-blockers, or combination therapy on prostatic size. With this study, one hundred and four patients with benign prostatic hyperplasia have been recruited from a private clinic in Kirkuk City in the period between 2019 and 2021. A radiologist conducted ultrasound assessments to measure the volume of the prostate in centimetres(cm³) both before and, after starting treatment. The follow-up ultrasound was performed two years after initiating the treatment. Prostatic volume has a dramatic decrease in patients on 5 alpha-reductase inhibiter or combination therapy. This change was statistically significant as the p-value was less than 0.05. On the other hand, patients on alpha-blocker therapy have a non-significant decrease in mean prostatic volume. In conclusion, 5 alpha reductase inhibiter when used alone or in combination with alpha blocker agents affects significantly prostatic size.